Global Cervical Dystonia Treatment Market 2023-2030

Description

List of Tables

Title: Global Cervical Dystonia Treatment Market Size, Share & Trends Analysis Report Market by Drug Type (Botulinum toxin, Anticholinergic agents, Dopaminergic agents, and Others), by Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), and by End-User (Hospitals, Clinics, and Others)Forecast Period (2023-2030).

The global cervical dystonia treatment market is anticipated to grow at a considerable CAGR of 7.8% during the forecast period. Cervical dystonia is a neurological disorder that causes the muscles in the neck to contract involuntarily. This can cause the head to lean or twist to one side, or the chin to pull up, down, forward, or backward. Primary factor propelling the market growth includes the increasing prevalence of cervical dystonia. According to the National Organization for Rare Disorders, Inc. (NORD), an estimated 60,000 people in the US are suffering with cervical dystonia. Furthermore, the estimated prevalence ranges from 5 to 30 cases per 100,000 individuals around the globe. Owing to such factors, there is significant increase in the demand for effective treatments of cervical dystonia. Botulinum toxin injections/ medications are considered the most effective and well-tolerated treatment. However, there are several developments of new and innovative treatment such as deep brain stimulation (DBS), and stem cell therapy, gene therapy, among others.

Segmental Outlook

The global cervical dystonia treatment market is segmented based on drug type, application and end-user type. Based on drug type, the market is segmented into botulinum toxin, anticholinergic agents, dopaminergic agents, and others. Based on application, the market is sub-segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Based on end-user, the market is sub-segmented into hospitals, clinics and others. Among the application, the hospital pharmacy is expected to hold a considerable share of the market, as most of the drugs prescribed for the treatment of cervical dystonia are not authorized to sale such drugs.

Botulinum Toxin Drug Type to Dominate the Global Cervical Dystonia Treatment Market

Among the drug type, the botulinum toxin sub-segment is expected to hold a prominent share of the market. It is the most common type of drug used to treat cervical dystonia owing to its high efficacy and safety. Thus, there is continuous and steady development and approval activities for botulinum toxin drugs around the globe. For instance, in 2021, the US FDA approved a new botulinum toxin medication named Daxxify. It is a more potent botulinum toxin that has been shown to be more effective than older botulinum toxin medications in treating cervical dystonia. Such approval activities will lead to an increase in the adoption of botulinum toxin injections and medications as the effective treatment of cervical dystonia.

Regional outlooks

The global cervical dystonia treatment market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Among these, North America is expected to dominate the market, owing to the presence of well-established research institutes and hospitals for treatment of cervical dystonia.

European Region to Hold a Prominent Share of the Global Cervical Dystonia Market

Among all regions, the European region is anticipated to hold a considerable share of the global cervical dystonia market. The growth is primarily owing to the rising prevalence of cervical dystonia in the region. According to the Dystonia UK Organization, the most common dystonia is the neck dystonia, which affects around 18,000 adults in the UK. Resultantly, there is a considerable increase in the adoption of various strategic initiatives such as collaborations and mergers, among others to reduce the number of cervical dystonia across the region by providing effective treatment. For instance, in August 2023, IPSEN announced its collaboration with Dystonia Europe to help uncover the unmet needs of people living with cervical dystonia. The project included the co-creation of the first ever cervical dystonia patient experience map, published in the Orphanet Journal of Rare Disease, which charted the experiences of 15 people living with cervical dystonia in the UK, France and Italy, from initial diagnosis to living with the condition day-to-day.

Market Players Outlook

The major companies serving the global cervical dystonia treatment market include AbbVie Inc., Ipsen Pharma, Merz Pharma GmbH & Co.KGaA., Revance Therapeutics, Inc., Hint, Inc., and USWM, LLC among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in August, 2023 , the Food and Drug Administration approved Daxxify (DaxibotulinumtoxinA-lanm; Revance Therapeutics, Nashville, TN) for its first therapeutic indication for injection to treat cervical dystonia in adults.

The Report Covers:

Market value data analysis of 2022 and forecast to 2030.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global cervical dystonia treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2027701

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. AbbVie Inc.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Ipsen Pharma
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Merz Pharma GmbH & Co.KGaA.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Revance Therapeutics, Inc., Hint, Inc.
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. USWM, LLC
- 3.6.1. Overview
- 3.6.2. Financial Analysis
- 3.6.3. SWOT Analysis
- 3.6.4. Recent Developments
3.7. Key Strategy Analysis

4. Market Segmentation

4.1. Global Cervical Dystonia Treatment Market by Drug Type
- 4.1.1. Botulinum Toxin
- 4.1.2. Anticholinergic Agents
- 4.1.3. Dopaminergic Agents
- 4.1.4. Others
4.2. Global Cervical Dystonia Treatment Market by Application
- 4.2.1. Hospital Pharmacy
- 4.2.2. Retail Pharmacy
- 4.2.3. Online Pharmacy
- 4.2.4. Others (Specialty Drug Stores)
4.3. Global Cervical Dystonia Treatment Markey by End-User
- 4.3.1. Hospitals
- 4.3.2. Clinics
- 4.3.3. Others (Clinical Research Organizations)

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Addex Pharma SA
6.2. Akorn Inc
6.3. Almirall, S.A.
6.4. Apotex Inc.
6.5. Astellas Pharma Inc.
6.6. BIOGEN INC.
6.7. Boehringer Ingelheim International GmbH
6.8. Bristol Myers Squibb Co.
6.9. DAIICHI SANKYO Co., Ltd.
6.10. Dr. Reddy's Laboratories Ltd.
6.11. Eisai Co., Ltd.
6.12. Galderma S.A.
6.13. H. Lundbeck A/S
6.14. Johnson & Johnson Services, Inc.
6.15. Kyowa Kirin Co., Ltd.
6.16. Lannett Co., Inc.
6.17. Mylan Pharmaceutical Pvt. Ltd.
6.18. Novartis AG.
6.19. Pfizer Inc.
6.20. Piramal Grp.
6.21. SANOFI
6.22. Sumitomo Pharma Co., Ltd.
6.23. Sun Pharmaceutical Ind., Ltd.
6.24. Teva Pharmaceutical Ind., Ltd.
6.25. UCB Biopharma SRL.